LA BioMed, an independent biomedical research organization, hosted its fifth annual Innovation Showcase on September 13th in Manhattan Beach. The event featured some of biotechnology’s most promising start-ups and spotlighted 32 promising new bioscience companies.
LA BioMed invites media to their fifth annual Innovation Showcase on September 13th at westdrift in Manhattan Beach, CA. The Showcase will highlight some of biotechnology’s most promising start-ups and venture capital leaders.
Biotech start-up entrants from the growing incubation hub of LA will showcase innovation in next generation medical therapies, devices and diagnostics from some of the worlds’ leading scientists. Highlights from the 32 featured companies include:
LA BioMed, an independent biomedical research organization, announced it will host its fifth annual Innovation Showcase on September 13th at westdrift Manhattan Beach. The Showcase highlights biotechnology’s most promising start-ups and venture capital leaders.
LA BioMed announced that it has closed on the sale of its $49,835,000 Series 2018 Tax-Exempt Revenue Bonds issued by the California Health Facilities Financing Authority (CHFFA). The proceeds of the revenue bond sale, which was led by Wells Fargo Securities, will be used to finance various capital improvements on the LA BioMed campus, including constructing and equipping a new biomedical res
A groundbreaking study by LA BioMed researchers shows promising results for a potential vaccine for deadly drug-resistant bacteria also known as superbugs.
LA BioMed announced the launch of two new male contraceptive studies. The preliminary study of the pill showed that the oral contraceptive appears to be safe and effective when taken daily. Current methods of male contraception include vasectomy, condoms, withdrawal, and fertility awareness.
LA BioMed spinoff, Emmaus Life Sciences has announced that The New England Journal of Medicine has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
Newly published study shows that strategies to curb inappropriate antibiotic prescribing which lead to deadly antibiotic resistant superbugs that kill an estimated 23,000 people each year are not only successful but also cost effective.